Dri Healthcare Trust · TSX:DHT.U
Dri Healthcare Trust — Q1 2026 Earnings Presentation
15 slides from Dri Healthcare Trust's earnings presentation, May 15, 2026
Slide 1: Advancing Science in the Pharmaceutical and Biotechnology Sector
Advancing Science in the Pharmaceutical and Biotechnology Sector First Quarter 2026 Earnings Call |May 15, 2026 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by DRI Healthcare Trust (“DRI Healthcare”). Established as an unincorporated open-ended trust in Ontario, Canada, and publicly trading since its 2021 IPO, DRI Healthcare is a global leader in providing financing to advance innovation in the life science
Slide 3: Ali Hedayat, Chief Executive Officer
Ali Hedayat Chief Executive Officer DRI Healthcare 3
Slide 4: Agenda
Agenda Ali Hedayat CEO Recent Highlights Navin Jacob Portfolio Update All Q&A CIO Zaheed Mawani CFO Financial Update 4
Slide 5: Recent Highlights
Recent Highlights Portfolio Balance Sheet Unitholder Performance Optimization Value • Record Q1 Total income of • Reduced Preferred securities • Q1 distribution of $0.11 per $50.6 million outstanding -- redeemed and Unit cancelled $9.9 million of face • Royalty Income growth of 18% value • Renewed N
Slide 6: Navin Jacob
Navin Jacob Executive Vice President, Investments & Chief Investment Officer, DRI Healthcare 6
Slide 7: Portfolio Performance
Portfolio Performance Portfolio assets show continued growth (millions of U.S. dollars) Q1 2026 Q1 2025 % Change 1 Q4 2025 % Change 1 TOTAL CASH RECEIPTS2 $58.4 $62.0 (6%) $50.7 15% 5.0 5.0 - - n/a 1.8 - n/a 0.8 123 1.2 1.1 3 1.9 (40) 1.4 1.9 (27) 1.4 (5) 8.7 8.0 9 8.8 (2) 1.0 1.5 (37) 0.9 7 3 26.9
Slide 8: Viridian (Veligrotug and elegrobart) Transaction Update
Viridian (Veligrotug and elegrobart) Transaction Update Third synthetic royalty transaction & second pre-approval transaction for DRI Product Summary Transaction Terms Product(s) Veligrotug & elegrobart US Net Sales ($M) Royalty Rates (%) • Royalty rates apply to annual U.S net sales of both product
Slide 9: Robust pipeline of over $3 billion in potential opportunities
Address important unmet needs with life-changing therapies for patients Robust pipeline of over $3 billion Marketed by leading biotech or biopharma companies in potential opportunities1 Provides strong intellectual property and regulatory protection 1. As of May 15, 2026. Represents the aggregate va
Slide 10: Zaheed Mawani
Zaheed Mawani Chief Financial Officer 10
Slide 11: Q1 2026 Financial Highlights
Q1 2026 Financial Highlights Total Cash Receipts1 Total income Adjusted EBITDA1 $58.4 million $50.6 million $52.8 million 6% over Q1 2025 15% over Q1 2025 2% over Q1 2025 Adjusted EBITDA Margin1 Adjusted Cash Earnings per Unit1 Declared Cash Distributions per Unit 90% $0.68 $0.11 1. Total Cash Recei
Slide 12: Strong Cash Generation
Strong Cash Generation Cash available to drive portfolio growth and maintain distributions to Unitholders Adjusted EBITDA1 for the Last Twelve Months Ended March 31, 2026 (millions) LTM Adjusted EBITDA Margin1 $205.1 ($0.3) ($1.7) ($2.5) ($1.0) 86% ($9.3) $1.2 $1.2 $192.8 ($21.9) -- -- ($2.7) ($2.2)
Slide 13: Well-Capitalized for Growth
Well-Capitalized for Growth Significant capacity for Cash and cash equivalents Royalties receivable Credit facility availability further $52.5 $54.3 $502.7 growth million1 million1 million1,2 1. As at March 31, 2026. 2. The increase in the availability of the credit facility is attributed to the pri
Slide 14: Efficient Execution & Disciplined Expense Management
Efficient Execution & Disciplined Expense Management Key priorities Strengthening Asset Risk Framework Disciplined Capital Allocation Focus on long-term, sustainable growth generating strong Unitholder returns 14
Slide 15: Thank you
Thank you Contact us Bill Zhang ir@drihealthcare.com 15